Home | Contact |
Rib-X Pharmaceuticals Initiates Delafloxacin Global Phase 3 Clinical Trial in Patients with Acute Bacterial Skin and Skin Structure Infections
Rib-X Pharmaceuticals Appoints John E. Sununu to the Board of Directors
Rib-X Pharmaceuticals Announces New Executive Leadership and Board of Directors Appointments
Rib-X Pharmaceuticals Appoints New Chair of Board of Directors
Rib-X Pharmaceuticals Closes First Tranche in $67.5 Million Financing
Rib-X Pharmaceuticals’ RX-04 Program will be featured at Windhover’s Therapeutic Area Partnerships Meeting as a “Top 10 Infectious Diseases Project to Watch”
Rib-X Pharmaceuticals Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA for Radezolid
Rib-X Pharmaceuticals Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA for Delafloxacin
Rib-X Reports Preclinical Studies at ICAAC with Novel Classes of RX-04 Antibiotic Compounds Demonstrating Potent and Rapid Efficacy in a S. pneumoniae Lung Model of Infection and Activity Against a Diverse Spectrum of Biodefense Pathogens
Rib-X Reports Additional Positive Delafloxacin Data at ICAAC, Including Performance against New Objective Endpoints from FDA, from its Completed Phase 2b Study in Patients with Acute Bacterial Skin and Skin Structure Infections
Rib-X Presents Data from Multiple Radezolid Studies at ICAAC Including Successful Intravenous Dosing in Phase 1 and Favorable Long-term Safety and Tolerability vs. Linezolid In Vivo
Rib-X Pharmaceuticals’ Antibiotic Development Programs to be Featured in 16 Posters and Symposium Sessions at ICAAC
Rib-X Pharmaceuticals Appoints Infectious Disease Expert and Former FDA Deputy Director Matthew Wikler, MD as Chief Development Officer
Rib-X Pharmaceuticals Receives $3 Million Milestone Payment from Sanofi in the RX-04 Collaboration
Rib-X Reports Positive Top-Line Data from Phase 2b Study of Delafloxacin in Patients with Acute Bacterial Skin and Skin Structure Infections
Rib-X Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Rib-X Pharmaceuticals' RX-04 Program Yields Compounds with In Vitro Potency Against Multi-drug Resistant P. aeruginosa
Rib-X Pharmaceuticals Presents Comprehensive Overview of RX-04 Program in 14 Posters at ICAAC
Rib-X Pharmaceuticals to Present 16 Posters Highlighting Data from its Antibiotic Development Programs at ICAAC
Rib-X Announces Senior Management Promotions
Rib-X Pharmaceuticals Named a 2011 Fierce 15 Company by FierceBiotech
Rib-X Pharmaceuticals Receives $9 Million Milestone Payment from Sanofi in the RX-04 Collaboration
Rib-X Pharmaceuticals and Sanofi Sign a Research Collaboration Agreement on Novel Classes of Antibiotics
Rib-X Pharmaceuticals Supports Generating Antibiotic Incentives Now (GAIN) Act
Rib-X Pharmaceuticals Presents Data at ECCMID Demonstrating Potent In Vitro Activity of Radezolid and Delafloxacin Against Resistant Strains of Gram-positive Bacteria Program
Rib-X Pharmaceuticals Presents Data at ECCMID for Three Novel Classes of Broad-spectrum Antibiotic Compounds From the RX-04 Development Program
Rib-X Pharmaceuticals to Present Six Abstracts at 21st Annual ECCMID/ 27th Annual ICC Conference
Rib-X Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference
Rib-X Pharmaceuticals to Present at 13th Annual Superbugs & Superdrugs Conference
Rib-X Initiates Phase 2b Study for Broad Spectrum Antibiotic Candidate Delafloxacin in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Rib-X Pharmaceuticals Raises $20 Million to Advance its Industry-Leading Antibiotics Pipeline
Rib-X Announces Publication Demonstrating Superior Infection Site Potency for Delafloxacin against Gram-positive Pathogens
Home | Contact | Terms | Site Map | © 2012 Rib-X Pharmaceuticals, Inc. All Rights Reserved.
